GeneDx(NASDAQ) WGS

Current Price$63.46

Market Cap$1.86B

Since IPO (2020)-81%

5 Year-84%

1 Year-24%

1 Month+9%

GeneDx last closing stock price
Metric	Price	Date
Last close	USD 63.38	2026-07-23

GeneDx stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.74%	USD 61.69	2026-07-16
1 month	+9.13%	USD 58.08	2026-06-23
3 month	-7.51%	USD 68.53	2026-04-24
Year to date	-51.27%	USD 130.06	2025-12-31
1 year	-23.59%	USD 82.95	2025-07-23
3 year	+714.65%	USD 7.78	2023-07-24
5 year	-83.81%	USD 391.38	2021-07-23
Since inception	-80.64%	USD 323.40	2020-11-04

GeneDx Financials at a Glance

Market Cap

$1.86B

Revenue (TTM)

$442.68M

Net Income (TTM)

-$77.81M

EPS (TTM)

-$2.67

P/E Ratio

-23.46

Dividend

$0.00

Beta (Volatility)

1.87 (High)

Dividend

$0.00

Beta (Volatility)

1.87 (High)

Price

$63.46

Volume

372,332

Open

$61.68

Price

$63.46

Volume

372,332

Open

$61.68

Previous Close

$63.38

Daily Range

$61.68 - $64.42

52-Week Range

$32.21 - $170.87

Estimated Earnings Date

Aug 3, 2026

Dividend

$0.00

Beta (Volatility)

1.87 (High)

Price

$63.46

Volume

372,332

Open

$61.68

Previous Close

$63.38

Daily Range

$61.68 - $64.42

52-Week Range

$32.21 - $170.87

Estimated Earnings Date

Aug 3, 2026

WGS News

What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%

Jonathan PoncianoJun 23, 2026

Hedge Funder Eli Casdin Is Loading up on GeneDx Shares

Brendan CoffeyJun 11, 2026

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

Jonathan PoncianoMay 23, 2026

Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?

Robert IzquierdoMay 21, 2026

Why GeneDX Stock Is Plummeting Today

Keith NoonanMay 5, 2026

GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?

Robert IzquierdoFeb 26, 2026

GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

Sarah SidlowDec 9, 2025

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

Adam PalascianoNov 14, 2025

Page 1

WGS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GeneDx

GeneDx helps doctors find answers for children with rare health conditions. The company uses DNA testing to diagnose complex medical problems quickly. These tests help families understand their health and plan better care.

Mapping the Genome

ExomeDx and GenomeDx: Advanced tests that scan DNA to find the cause of rare diseases in children and adults.
GeneDx Infinity: Collection of genetic data used to make medical diagnoses faster and more precise.
Genomic Newborn Screening: Early testing protocols for babies to find health issues before symptoms appear.
Biopharma Solutions: Data services that help drug companies find patients for medical research and clinical trials.

Growing the Network

Acquired Fabric Genomics in May 2025 to add cloud-based tools for analyzing genetic data.
Merged with Legacy GeneDx in April 2022 to focus the business on large-scale genomic testing.
Received Breakthrough Device Designation from the FDA in October 2025 for its core diagnostic tests.
Collaborated on the GUARDIAN study to test the use of DNA sequencing for screening all newborns.

What Makes GeneDx Different?

The firm manages a rare disease dataset containing over 2.5 million tests and 8 million patient data points. It uses artificial intelligence (AI), or computer learning, to process this information and identify genetic variants that other tests might miss.

Performance by the Numbers

Revenue was $121 million in Q4 2025, up 26.5% from the previous year.
Gross profit reached $78.9 million in Q4 2025, a 19.2% increase year-over-year.
Net income fell to -$17.7 million in Q4 2025, down 424.9% from $5.4 million in Q4 2024.
Operating cash flow was -$3.1 million in Q4 2025, an improvement of 2.9% from Q4 2024.
Market capitalization grew to $3.5 billion in Q4 2025, up 68.6% year-over-year.

Evolution into Intelligence

GeneDx has shifted from a traditional laboratory to a data-driven health intelligence firm. Its focus on combining massive genomic datasets with AI supports its goal of making DNA sequencing the standard for medical diagnosis.

AI Generated • Apr 28, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

1,300

CEO

Katherine A. Stueland

Website

www.genedx.com

Headquarters

Stamford, CT 06902, US

WGS Financials

Key Financial Metrics (TTM)

Gross Margin

68.35%

Operating Margin

-7.72%

Net Income Margin

-17.58%

Return on Equity

-27.50%

Return on Capital

-2.56%

Return on Assets

-15.37%

Earnings Yield

-4.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.86B

Shares Outstanding

29.69M

Volume

372.33K

Avg. Volume

1.33M

Financials (TTM)

Gross Profit

$302.56M

Operating Income

-$34.19M

EBITDA

-$48.50M

Operating Cash Flow

-$9.31M

Capital Expenditure

-$19.34M

Free Cash Flow

-$28.65M

Cash & ST Invst.

$170.69M

Total Debt

$168.19M

GeneDx Performance Analysis

GeneDx annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 234,694,000	10.6%
2023	2023-12-31	USD 202,566,000	-13.7%
2024	2024-12-31	USD 305,450,000	50.8%
2025	2025-12-31	USD 427,539,000	40.0%

GeneDx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	17.9%
Q3	2025-09-30	13.7%
Q4	2025-12-31	3.6%
Q1	2026-03-31	-15.5%

GeneDx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -53.63	-28.4%
2023	2023-12-31	USD -7.23	-86.5%
2024	2024-12-31	USD -1.94	-73.1%
2025	2025-12-31	USD -0.73	-62.3%

GeneDx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	256.5%
Q3	2025-09-30	-175.0%
Q4	2025-12-31	-118.5%
Q1	2026-03-31	-266.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$102.25M

+17.4%

Gross Profit

$68.21M

+16.6%

Gross Margin

66.71%

N/A

Market Cap

$1.86B

N/A

Market Cap/Employee

$1.43M

N/A

Employees

1,300

N/A

Net Income

-$63.32M

-869.8%

EBITDA

-$54.89M

-23359.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$170.69M

+7.2%

Total Debt

$168.19M

+46.5%

Accounts Receivable

$76.93M

+67.0%

Inventory

$12.24M

-3.3%

Long Term Debt

$163.06M

+46.0%

Short Term Debt

$5.13M

+64.2%

Return on Assets

-15.37%

N/A

Return on Invested Capital

-8.17%

N/A

Free Cash Flow

-$38.86M

-1058.8%

Operating Cash Flow

-$32.41M

-418.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TMDXTransMedics Group, Inc.

TMDXTransMedics Group, Inc.$71.13-0.10%

PRVAPrivia Health Group, Inc.

PRVAPrivia Health Group, Inc.$24.97-1.58%

OPCHOption Care Health, Inc.

OPCHOption Care Health, Inc.$21.08-0.33%

NAMSNewAmsterdam Pharma Company N.V.

NAMSNewAmsterdam Pharma Company N.V.$30.55-3.63%

VKTXViking Therapeutics, Inc.

VKTXViking Therapeutics, Inc.$35.39-5.15%

HNGEHinge Health, Inc.

HNGEHinge Health, Inc.$76.69-3.02%

OSCROscar Health, Inc.

OSCROscar Health, Inc.$28.92-1.97%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.76-0.29%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.56-0.08%

SMCISuper Micro Computer

SMCISuper Micro Computer$31.20+0.02%

ONDSOndas

ONDSOndas$7.93-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$66.30-0.06%

HBANHuntington Bancshares

HBANHuntington Bancshares$17.40-0.05%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$10.96+0.16%

Questions About WGS

What is the current price of GeneDx?

GeneDx is trading at $63.38 per share.

What is the 52-week range for GeneDx?

Over the past 52 weeks, GeneDx has traded between $32.21 and $170.87.

How much debt does GeneDx have?

As of the most recent reporting period, GeneDx reported total debt of $168.19M.

How much cash does GeneDx have on hand?

GeneDx reported $93.92M in cash and cash equivalents in its most recent financial results.

What is GeneDx’s dividend yield?

GeneDx does not currently have a dividend yield.

GeneDx(NASDAQ) WGS

GeneDx Financials at a Glance

WGS News

What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%

Hedge Funder Eli Casdin Is Loading up on GeneDx Shares

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%

Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?

Why GeneDX Stock Is Plummeting Today

GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?

GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

WGS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About GeneDx

Mapping the Genome

Growing the Network

What Makes GeneDx Different?

Performance by the Numbers

Evolution into Intelligence

WGS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

GeneDx Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About WGS

What is the current price of GeneDx?

What is the 52-week range for GeneDx?

How much debt does GeneDx have?

How much cash does GeneDx have on hand?

What is GeneDx’s dividend yield?

Premium Investing Services